Anavex Life Sciences Corp. has a productive drug discovery platform. Several drugs with new mechanism of action are near clinical trials in Central Nervous System (CNS) and Oncology. Anavex has a broad IP portfolio based on unique expertise of sigma receptors ligands. Several Anavex new drug candidates with high affinity for sigma receptors are close to entering Phase I or Phase II clinical trials. The synergetic effects of sigma receptors offer a new neuroprotective mechanism in Alzheimer’s disease and other CNS disorders such as epilepsy and depression. Anavex proprietary sigma ligands induce apoptosis in cancer cells in a selective way. Anavex oncology candidates show promising pro-apoptotic activity in several in vivo models of solid tumors.

Diseases like Alzheimer’s, epilepsy and cancer affect millions of people worldwide, causing enormous suffering and burden - the worldwide prevalence of Alzheimer’s alone was over 26 million in 2006, as reported by Johns Hopkins University, and is expected to quadruple by 2050. With the rise of a new middle class in emerging markets and the aging of baby boomers, demand is increasing for treatments for these major devastating diseases.